Abstract

Long-term potentiation (LTP) at hippocampal CA1 synapses can be expressed by an increase either in the number (N) of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors or in their single channel conductance (γ). Here, we have established how these distinct synaptic processes contribute to the expression of LTP in hippocampal slices obtained from young adult rodents. LTP induced by compressed theta burst stimulation (TBS), with a 10 s inter-episode interval, involves purely an increase in N (LTPN). In contrast, either a spaced TBS, with a 10 min inter-episode interval, or a single TBS, delivered when PKA is activated, results in LTP that is associated with a transient increase in γ (LTPγ), caused by the insertion of calcium-permeable (CP)-AMPA receptors. Activation of CaMKII is necessary and sufficient for LTPN whilst PKA is additionally required for LTPγ. Thus, two mechanistically distinct forms of LTP co-exist at these synapses.

Long-term potentiation at hippocampal CA1 synapses can be due to increasing the number and/or single-channel conductance of AMPA receptors. The authors show that PKA and CaMKII are necessary and together sufficient to increase single channel conductance, via insertion of calcium-permeable AMPA receptors.

Details

Title
PKA drives an increase in AMPA receptor unitary conductance during LTP in the hippocampus
Author
Park Pojeong 1 ; Georgiou, John 2   VIAFID ORCID Logo  ; Sanderson, Thomas M 3   VIAFID ORCID Logo  ; Kwang-Hee, Ko 4 ; Kang, Heather 1 ; Ji-il, Kim 4 ; Bradley, Clarrisa A 5   VIAFID ORCID Logo  ; Bortolotto, Zuner A 6   VIAFID ORCID Logo  ; Zhuo, Min 7   VIAFID ORCID Logo  ; Kaang Bong-Kiun 4   VIAFID ORCID Logo  ; Collingridge, Graham L 8   VIAFID ORCID Logo 

 University of Bristol, Glutamate Receptor Group, School of Physiology, Pharmacology and Neuroscience, Bristol, United Kingdom (GRID:grid.5337.2) (ISNI:0000 0004 1936 7603); Seoul National University, Department of Biological Sciences, College of Natural Sciences, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada (GRID:grid.416166.2) (ISNI:0000 0004 0473 9881); University of Toronto, Department of Physiology, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938) 
 Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada (GRID:grid.416166.2) (ISNI:0000 0004 0473 9881) 
 University of Bristol, Glutamate Receptor Group, School of Physiology, Pharmacology and Neuroscience, Bristol, United Kingdom (GRID:grid.5337.2) (ISNI:0000 0004 1936 7603); Seoul National University, Department of Biological Sciences, College of Natural Sciences, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada (GRID:grid.416166.2) (ISNI:0000 0004 0473 9881) 
 Seoul National University, Department of Biological Sciences, College of Natural Sciences, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905) 
 Seoul National University, Department of Biological Sciences, College of Natural Sciences, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); The Hospital for Sick Children, Neurosciences and Mental Health, Peter Gilgan Centre for Research and Learning, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646) 
 University of Bristol, Glutamate Receptor Group, School of Physiology, Pharmacology and Neuroscience, Bristol, United Kingdom (GRID:grid.5337.2) (ISNI:0000 0004 1936 7603) 
 Seoul National University, Department of Biological Sciences, College of Natural Sciences, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); University of Toronto, Department of Physiology, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938) 
 University of Bristol, Glutamate Receptor Group, School of Physiology, Pharmacology and Neuroscience, Bristol, United Kingdom (GRID:grid.5337.2) (ISNI:0000 0004 1936 7603); Seoul National University, Department of Biological Sciences, College of Natural Sciences, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada (GRID:grid.416166.2) (ISNI:0000 0004 0473 9881); University of Toronto, Department of Physiology, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); University of Toronto, TANZ Centre for Research in Neurodegenerative Diseases, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2478661137
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.